Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.78 |
| ▸ | BLM | P54132 | 5/20 | 0.78 |
| ▸ | MEN1 | O00255 | 5/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | CASP3 | P42574 | 5/20 | 0.78 |
| ▸ | SENP8 | Q96LD8 | 5/20 | 0.78 |
| ▸ | SENP7 | Q9BQF6 | 5/20 | 0.78 |
| ▸ | SENP6 | Q9GZR1 | 5/20 | 0.78 |
| ▸ | APAF1 | O14727 | 5/20 | 0.78 |
| ▸ | TDP2 | O95551 | 3/20 | 0.78 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.78 |
| ▸ | UBA2 | Q9UBT2 | 2/20 | 0.78 |
| ▸ | NSD2 | O96028 | 2/20 | 0.78 |
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | GALK1 | P51570 | 2/20 | 0.78 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29597370 | 1.00 | L3MBTL1 (0.78) | L3MBTL1BLMMEN1KMT2ACASP3 | |
| SCHEMBL24355093 | 0.84 | MAPT (0.63) | L3MBTL1BLMMEN1KMT2ACASP3 | |
| SCHEMBL30494359 | 0.83 | MAPT (0.75) | L3MBTL1BLMMEN1KMT2ACASP3 | |
| SCHEMBL28675538 | 0.83 | MAPT (0.75) | L3MBTL1BLMMEN1KMT2ACASP3 | |
| SCHEMBL7912631 | 0.82 | MAPT (0.80) | L3MBTL1BLMMEN1KMT2ACASP3 | |
| SCHEMBL754259 | 0.82 | MAPT (1.00) | L3MBTL1BLMMEN1KMT2ACASP3 | |
| SCHEMBL29633257 | 0.82 | MAPT (1.00) | L3MBTL1BLMMEN1KMT2ACASP3 | |
| SCHEMBL28408126 | 0.80 | MAPT (0.96) | L3MBTL1BLMMEN1KMT2ACASP3 | |
| SCHEMBL16297260 | 0.80 | MAPT (0.75) | L3MBTL1BLMMEN1KMT2ACASP3 | |
| SCHEMBL14571425 | 0.80 | MAPT (0.77) | L3MBTL1BLMMEN1KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220128562-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | UNIVERSITY OF KANSAS | 2022-04-28 | — | — | US | claimed |
| WO-2020112672-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-04 | — | — | WO | claimed |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | UNIVERSITY OF KANSAS | 2017-11-23 | — | — | US | claimed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | claimed |
| US-9745261-B2 | Inhibitors of the MITF molecular pathway | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-29 | — | — | US | claimed |
| EP-3191087-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | Pellficure Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE BROAD INSTITUTE, INC. | 2016-05-12 | — | — | US | claimed |
| EP-3007688-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | The General Hospital Corporation (US) | 2016-04-20 | — | — | EP | claimed |
| WO-2016040896-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| WO-2014201016-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-18 | — | — | WO | claimed |
| US-12560609-B2 | Biomarkers predictive of cancer cell response to ML329 or a derivative thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250101435-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-27 | — | — | US | disclosed |
| US-20240052354-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-02-15 | — | — | US | disclosed |
| US-11530413-B2 | Compositions and methods to treat cancer | NOVARTIS AG (CH) | 2022-12-20 | — | — | US | disclosed |
| US-11530413-B2 | Compositions and methods to treat cancer | NOVARTIS AG (CH) | 2022-12-20 | — | — | US | disclosed |
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE BROAD INSTITUTE, INC. | 2016-05-12 | — | — | US | disclosed |
| EP-3007688-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | The General Hospital Corporation (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2016040896-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2014201016-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014201016-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240052354-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | TP53, BRCA1, NTPCR | L3MBTL1 3586/4885BLM 77/4885MEN1 1429/4885 |
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | MITF, TFEB, TYR | L3MBTL1 2967/4885BLM 2674/4885MEN1 1616/4885 |
| US-11530413-B2 | Compositions and methods to treat cancer | TP53, BRCA1, NTPCR | L3MBTL1 3586/4885BLM 77/4885MEN1 1429/4885 |
| US-12560609-B2 | Biomarkers predictive of cancer cell response to ML329 or a derivative thereof | KEAP1, NFE2L2, NQO1 | L3MBTL1 231/4885BLM 2610/4885MEN1 2749/4885 |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | L3MBTL1 4625/4885BLM 564/4885MEN1 260/4885 |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | MITF, TFEB, TYR | L3MBTL1 2985/4885BLM 2744/4885MEN1 1568/4885 |
| US-20250101435-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | TP53, BRCA1, NTPCR | L3MBTL1 3586/4885BLM 77/4885MEN1 1429/4885 |
| US-20220128562-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | NQO1, KEAP1, NFE2L2 | L3MBTL1 475/4885BLM 1524/4885MEN1 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.